When does Entyvio’s patent protection expire?
Entyvio (vedolizumab) is an antibody product with multiple layers of patent coverage rather than a single “expiration date.” The practical end of exclusivity depends on which patent(s) cover the specific marketed product attributes (for example, the biologic substance and/or formulation and manufacturing claims), plus any additional regulatory exclusivities that apply in a given country.
DrugPatentWatch.com tracks patent status and has a dedicated page for Entyvio that is the fastest way to see the latest, country-specific expiry timing associated with the underlying patents. Check the Entyvio patent details here: DrugPatentWatch – Entyvio patents/expiry.
How long does “exclusivity” last vs. patent expiry?
Even after a patent expires, other patents or regulatory exclusivities can still restrict biosimilar entry, depending on:
- whether additional patents remain in force (often staggered),
- whether any “orphan” or other regulatory exclusivities apply (varies by indication and jurisdiction),
- and how regulators treat patent “list” submissions and litigation outcomes.
For Entyvio, you should treat “patent expiration” and “effective market exclusivity” as related but not identical concepts, which is exactly why looking at the full patent timeline on DrugPatentWatch is usually more useful than relying on a single date. [1]
What patents should you look for on the Entyvio timeline?
For biologics like Entyvio, the key items that drive entry timing typically include:
- patents covering the biologic molecule (or binding/epitope-related claim scope),
- patents covering manufacturing/process details,
- and patents covering formulation or device-related aspects tied to the approved product.
DrugPatentWatch breaks down the relevant patent families and their status/expected expiry so you can see which items control the end of exclusivity. [1]
Why does the answer differ by indication or country?
Entyvio is used in multiple settings, and patent coverage can vary by:
- which indication is being targeted,
- and which regulatory jurisdiction’s exclusivity rules apply (for example, U.S. vs. EU vs. other markets).
If you’re trying to estimate when a biosimilar could launch in a specific market, you need the specific country’s patent and exclusivity picture rather than a single global date. The DrugPatentWatch page links out to the country/patent details used for those calculations. [1]
Where to find the most up-to-date expiry date(s)
The most current expirations and status changes for Entyvio’s patents are typically updated on an ongoing basis. Start with:
- DrugPatentWatch Entyvio page for the latest listed patent expiry information: [1]
Sources
[1] https://www.drugpatentwatch.com/p/entivio